Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

Cyrus V. Desouza; Vijay Shivaswamy

doi:10.4137/CMED.S5372

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

Cyrus V. Desouza, Vijay Shivaswamy

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Abstract

The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPAR-gamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.

Original language	English (US)
Journal	Clinical Medicine Insights: Endocrinology and Diabetes
Volume	3
DOIs	https://doi.org/10.4137/CMED.S5372
State	Published - Jan 2010

Keywords

Pioglitazone
cardiovascular
diabetes
efficacy
safety

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.4137/CMED.S5372

Cite this

@article{deeccc5db53743d389080465aa5c67f9,

title = "Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review",

abstract = "The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPAR-gamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.",

keywords = "Pioglitazone, cardiovascular, diabetes, efficacy, safety",

author = "Desouza, {Cyrus V.} and Vijay Shivaswamy",

note = "Publisher Copyright: {\textcopyright} 2010 SAGE Publications.",

year = "2010",

month = jan,

doi = "10.4137/CMED.S5372",

language = "English (US)",

volume = "3",

journal = "Clinical Medicine Insights: Endocrinology and Diabetes",

issn = "1179-5514",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Pioglitazone in the Treatment of Type 2 Diabetes

T2 - Safety and Efficacy Review

AU - Desouza, Cyrus V.

AU - Shivaswamy, Vijay

PY - 2010/1

Y1 - 2010/1

N2 - The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPAR-gamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.

AB - The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPAR-gamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.

KW - Pioglitazone

KW - cardiovascular

KW - diabetes

KW - efficacy

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85127246273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127246273&partnerID=8YFLogxK

U2 - 10.4137/CMED.S5372

DO - 10.4137/CMED.S5372

M3 - Review article

AN - SCOPUS:85127246273

SN - 1179-5514

VL - 3

JO - Clinical Medicine Insights: Endocrinology and Diabetes

JF - Clinical Medicine Insights: Endocrinology and Diabetes

ER -

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this